Seagen is a Washington-based biotechnology company that develops and commercializes therapies for the treatment of cancer.
Business Model:
Revenue: $1.9B
Employees: 1,001-5,000
Address: 21717 30th Drive S.E
City: Bothell
State: WA
Zip: 98021
Country: US
Seagen is a Washington-based biotechnology company that develops and commercializes therapies for the treatment of cancer.
Contact Phone:
+14255274000
Contact Email:
Listed Exchange:
NASDAQ
IPO Date:
3/16/2001
Ticker Symbol:
SGEN
Amount Raised:
$49M
Opened: -/share
EBITDA | - |
Total Cash | - |
Total Debt | - |
Total Revenue | - |
Total Profit (Gross) | - |
PE Ratio | - |
Announced Date | Company | Transaction | Money Raised |
---|---|---|---|
1/2023 | Pieris Pharmaceuticals | Post-IPO Equity | 5M |
6/2015 | Cogent Biosciences | Series B | 65M |
6/2015 | Cogent Biosciences | Series B | 0 |
Announced Date | Transaction | Number of Investors | Money Raised | Lead Investors | 1/2014 | Post-IPO Equity | 1 | $9M |
Takeda Takeda |
1/2009 | Post-IPO Equity | 1 | - |
New Enterprise Associates New Enterprise Associates |
3/2001 | IPO | $49M | 5/2009 | Equity | $11.5M | 7/2019 | Post-IPO Equity | $575M | 1/1998 | Venture Round | 1 | - |
Sofinnova Investments Sofinnova Investments |
9/2020 | Post-IPO Equity | 1 | $1B |
Merck Sharp &a; Dohme Sweden AB Merck Sharp &a; Dohme Sweden AB Merck Sharp &a; Dohme Sweden AB Merck Sharp &a; Dohme Sweden AB |
2/2011 | Post-IPO Equity | $155M | 1/2009 | Post-IPO Equity | 1 | - |
New Enterprise Associates New Enterprise Associates |
1/1998 | Venture Round | 1 | - |
Sofinnova Investments Sofinnova Investments |
---|
Announced Date | Name | Price |
---|---|---|
1/2018 | Cascadian Therapeutics |
|
Revenue: 0 - 100000 Employees: Industry: Software |
Details
|
|
Revenue: 0 - 100000 Employees: 51 - 500 Industry: Education |
Details
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Blockchain |
Details
|
|
Revenue: 0 - 100000 Employees: 11 - 50 Industry: Industrial |
Details
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Advertising |
Details
|